Neogen Corporation stock holds at USD 13 as revenue falls

Published on 09/22/2026 at 08:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neogen Corporation stock was quoted at USD 13.00 on September 21, 2026, with a USD 2.835 billion market cap. Q2 FY26 revenue was USD 1 billion.

NEOG, US6404911066, Illustration mit AI erstellt.

Neogen Corporation (ISIN US6404911066) was quoted at USD 13.00 on Nasdaq on September 21, 2026, up 1.33 percent, with a market capitalization of USD 2.835 billion. The market data also identify the latest quarterly revenue as USD 1 billion in Q2 FY26, while diluted trailing EPS stood at negative USD 4.81.

Revenue reaches USD 1 billion

Neogen reported quarterly revenue of USD 1 billion for Q2 FY26, according to the financial data published on September 21, 2026. The same data show a profit margin of negative 0.15 percent and diluted trailing EPS of negative USD 4.81, placing profitability alongside revenue growth as the central operating measure.

The comparison is stark: revenue reached the billion-dollar level, while the trailing earnings figure remained negative at USD 4.81 per share. That gap gives the stock a very different profile from a company valued primarily on current earnings.

Nasdaq quote and valuation

At USD 13.00 on September 21, 2026, Neogen had a market capitalization of USD 2.835 billion. The daily change was positive 1.33 percent, but the available quote does not establish a new high or a break of a specific chart level.

For investors, the most important numerical relationship is therefore the balance between the USD 1 billion Q2 FY26 revenue base and negative USD 4.81 trailing EPS. Revenue provides scale; the negative earnings figure shows that the conversion of that scale into profit remains the harder question.

Stock remains tied to earnings

Neogen Corporation stock closed at USD 13.00 on Nasdaq as of September 21, 2026. The quoted market capitalization of USD 2.835 billion and the Q2 FY26 revenue figure of USD 1 billion provide the clearest dated reference points for assessing the company without adding an unsupported price target.